Table 1 Subject-, disease-, and transplant-related variables
Characteristics | ATG-PTCy cohort (n = 114) | ATG cohort (n = 125) | P value |
|---|---|---|---|
Recipient age (year, median, range) | 27 (5–52) | 24 (4–65) | 0.004 |
HLA-matching (A, B, DR) | 0.001 | ||
 3/6 | 94 (82%) | 78 (62%) |  |
 4/6 or 5/6 | 20 (18%) | 47 (38%) |  |
Recipient gender | 0.35 | ||
 Male | 63 (55%) | 77 (62%) |  |
 Female | 51 (45%) | 48 (38%) |  |
Disease type | 0.99 | ||
 Acute myeloid leukemia (AML) | 55 (48%) | 59 (47%) |  |
 Acute lymphoblastic leukemia (ALL) | 47 (41%) | 52 (42%) |  |
 Myelodysplastic syndromes (MDS) | 9 (8%) | 11 (9%) |  |
 Chronic myeloid leukemia (CML) | 3 (3%) | 3 (2%) |  |
Disease risk index | 0.20 | ||
 Low/intermediate | 101 (88%) | 103 (83%) |  |
 High/very high | 13 (12%) | 22 (17%) |  |
Minimal residual disease at transplant | 0.86 | ||
 Negative | 93 (82%) | 104 (83%) |  |
 Positive | 21 (18%) | 21 (17%) |  |
Donor source | 0.19 | ||
 Mother | 80 (70%) | 98 (78%) |  |
 Collateral relatives | 34 (30%) | 27 (22%) |  |
  Donor gender male vs female | 27 vs 7 | 20 vs 7 |  |
  Donor age (year, median, range) | 46 (12–67) | 42 (10–61) |  |
  Maternal vs paternal line | 20 vs 14 | 19 vs 8 |  |
Donor gender | 0.15 | ||
 Male | 27 (24%) | 20 (16%) |  |
 Female | 87 (76%) | 105 (84%) |  |
Donor-recipient pair | 0.20 | ||
 Female to male | 68 (60%) | 64 (51%) |  |
 Others | 46 (40%) | 61 (49%) |  |
Donor age (year, median, range) | 46 (12–67) | 42 (10–61) | 0.002 |
Blood type matching | 0.020 | ||
 Match | 51 (45%) | 75 (60%) |  |
 Mismatch | 63 (55%) | 50 (40%) |  |
Median mononuclear cell (range, 108/kg) | 8.2 (3.3–11.8) | 10.4 (3.8–26.1) | < 0.001 |
Median CD34+ cells (range, 106/kg) | 1.9 (0.5–14.1)) | 3.4 (1.6–21.2) | < 0.001 |
Median CD3+ cells (range, 108/kg) | 1.4 (0.3–5.7) | 1.5 (0.3–11.1) | 0.63 |
Year of transplant | 0.006 | ||
 April 2015 to August 2016 | 40 (35%) | 66 (53%) |  |
 September 2016 to June 2018 | 74 (65%) | 59 (47%) |  |
Median follow-up (range, days) | 587 (57–1399) | 682 (3–1448) | 0.20 |
Median follow-up in survivors (range, days) | 661 (128–1399) | 859 (230–1448) | 0.007 |